S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Global markets are mixed as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
Biden administration agrees to provide $6.4 billion to Samsung for making computer chips in Texas
The IRS is quicker to answer the phone on this Tax Day
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Global markets are mixed as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
Biden administration agrees to provide $6.4 billion to Samsung for making computer chips in Texas
The IRS is quicker to answer the phone on this Tax Day
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Global markets are mixed as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
Biden administration agrees to provide $6.4 billion to Samsung for making computer chips in Texas
The IRS is quicker to answer the phone on this Tax Day
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Global markets are mixed as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
Biden administration agrees to provide $6.4 billion to Samsung for making computer chips in Texas
The IRS is quicker to answer the phone on this Tax Day
NYSE:ZBH

Zimmer Biomet (ZBH) Stock Price, News & Analysis

$124.48
-3.04 (-2.38%)
(As of 04/12/2024 08:52 PM ET)
Today's Range
$123.71
$127.10
50-Day Range
$121.84
$132.61
52-Week Range
$102.00
$149.25
Volume
1.05 million shs
Average Volume
1.49 million shs
Market Capitalization
$25.58 billion
P/E Ratio
25.46
Dividend Yield
0.77%
Price Target
$139.39

Zimmer Biomet MarketRank™ Stock Analysis

Analyst Rating
Hold
2.27 Rating Score
Upside/​Downside
12.0% Upside
$139.39 Price Target
Short Interest
Healthy
2.31% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-1.33
Upright™ Environmental Score
News Sentiment
1.19mentions of Zimmer Biomet in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$3.36 M Sold Last Quarter
Proj. Earnings Growth
7.93%
From $8.07 to $8.71 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.73 out of 5 stars

Medical Sector

80th out of 928 stocks

Surgical Appliances & Supplies Industry

2nd out of 17 stocks

ZBH stock logo

About Zimmer Biomet Stock (NYSE:ZBH)

Zimmer Biomet Holdings Inc is a medical technology company that designs, develops and manufactures a wide range of orthopedic and musculoskeletal products. With headquarters in Warsaw, Indiana, the company was formed in 2015 after the merger of Zimmer Holdings and Biomet Inc, two of the world's leading companies in the orthopedic industry. Zimmer Biomet's mission is to help people alleviate pain, regain mobility and improve the quality of life for patients worldwide.

The company's leadership team is led by President and CEO Bryan Hanson, who has been in his current role since 2017. Hanson has over 30 years of experience in the medical device industry and has held various executive positions in leading medical device companies. Additionally, Zimmer Biomet's executive team includes Chief Financial Officer Suketu Upadhyay and Chief Operating Officer Ivan Tornos. 

Over the past few years, Zimmer Biomet has reported steady financial performance. The company has reported increased revenue and profit margin for the past several years while also reporting a debt-to-equity ratio indicating a relatively low debt level. In 2021, the company also announced a share repurchase program of up to $1 billion, demonstrating its commitment to returning value to shareholders.

Zimmer Biomet's stock performance has been mixed over the past few years. In early 2020, the company's stock price experienced a sharp decline due to the COVID-19 pandemic, but since then, it has rebounded and continues to experience volatility. 

The orthopedic industry is highly competitive, with a few major players dominating the market. Zimmer Biomet is one of the largest companies in the industry, with a strong presence in the joint reconstruction, spine, dental, and sports medicine markets. The industry is also highly regulated, with various regulatory bodies overseeing the safety and efficacy of medical devices. Zimmer Biomet has a track record of complying with regulatory requirements and maintaining high-quality standards.

Zimmer Biomet is expanding its product portfolio through innovation and acquisitions. The company has a robust pipeline of new products in development, including the Persona Revision Knee System and the ROSA Knee System. Zimmer Biomet is also pursuing strategic acquisitions to expand its presence in emerging markets and strengthen its position in existing markets.

One of the most significant risks facing Zimmer Biomet is the potential for regulatory changes that could impact the industry. Changes in regulatory requirements could increase the costs and time required to bring new products to market, affecting Zimmer Biomet's ability to innovate and compete. In addition, insurance and hospital reimbursement policy changes could also impact the demand for Zimmer Biomet's products.

Another risk facing Zimmer Biomet is the potential for increased competition. While the company is one of the most significant players in the orthopedic industry, it faces competition from other established companies and new entrants. To maintain its market position, Zimmer Biomet must continue to innovate and invest in research and development.

Finally, changes in consumer preferences and healthcare trends could impact demand for Zimmer Biomet's products. For example, the increasing popularity of non-surgical treatments for orthopedic conditions could affect the demand for joint replacement products.

ZBH Stock Price History

ZBH Stock News Headlines

Buy Alert
Imagine knowing, ahead of time, what the best investments of the year would be… Well, investors no longer need to imagine, guess, or throw darts. See, we’ve uncovered what looks to be a list of THE 10 best opportunities for 2024.
Unveiling 7 Analyst Insights On Zimmer Biomet Holdings
Buy Alert
Imagine knowing, ahead of time, what the best investments of the year would be… Well, investors no longer need to imagine, guess, or throw darts. See, we’ve uncovered what looks to be a list of THE 10 best opportunities for 2024.
Zimmer Biomet Holdings Inc.
Zimmer Biomet Holdings, Inc.
Zimmer Biomet Receives FDA's 510(k) Clearance For ROSA Shoulder System
Q1 2024 Neuroone Medical Technologies Corp Earnings Call
See More Headlines
Receive ZBH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zimmer Biomet and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 1/31 Dividend
12/26/2023
Dividend Payable
1/31/2024
Last Earnings
2/08/2024
Ex-Dividend for 4/30 Dividend
3/27/2024
Today
4/14/2024
Dividend Payable
4/30/2024
Next Earnings (Confirmed)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical appliances & supplies
Sub-Industry
N/A
Employees
18,000
Year Founded
1927

Price Target and Rating

Average Stock Price Target
$139.39
High Stock Price Target
$172.00
Low Stock Price Target
$120.00
Potential Upside/Downside
+12.0%
Consensus Rating
Hold
Rating Score (0-4)
2.27
Research Coverage
15 Analysts

Profitability

Net Income
$1.02 billion
Pretax Margin
14.43%

Debt

Sales & Book Value

Annual Sales
$7.39 billion
Cash Flow
$12.13 per share
Book Value
$59.76 per share

Miscellaneous

Free Float
203,509,000
Market Cap
$25.58 billion
Optionable
Optionable
Beta
1.01

Social Links

10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Ivan Tornos (Age 49)
    COO, President, CEO & Director
    Comp: $2.05M
  • Mr. Suketu P. Upadhyay (Age 55)
    CFO and Executive VP of Finance, Operations & Supply Chain
    Comp: $1.81M
  • Mr. Chad F. PhippsMr. Chad F. Phipps (Age 52)
    Senior VP, General Counsel & Secretary
    Comp: $1.23M
  • Mr. Sang YiMr. Sang Yi (Age 62)
    President of Asia Pacific
    Comp: $1.36M
  • Mr. Paul A. Stellato (Age 49)
    VP, Controller & Chief Accounting Officer
  • Dr. Nitin Goyal M.D.
    Chief Science, Technology & Innovation Officer
  • Mr. Zeeshan Tariq
    Senior VP & Chief Information Officer
  • Ms. Keri P. Mattox
    SVP and Chief Communications & Administration Officer
  • Mr. Zachary Ross Weiner CPA
    Director of Investor Relations
  • Ms. Angela Main
    Senior VP, Global Chief Compliance Officer & Associate General Counsel of Asia Pacific

Should I Buy Zimmer Biomet Stock? ZBH Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Zimmer Biomet Holdings, Inc.:

  • Zimmer Biomet Holdings, Inc. operates as a global medical technology company, providing a diverse range of orthopedic reconstructive products, including knee and hip products, which are essential in the healthcare industry.
  • The company offers innovative robotic, surgical, and bone cement products, showcasing a commitment to technological advancements in the medical field, potentially leading to increased market share and revenue growth.
  • Recent institutional investments in Zimmer Biomet Holdings, Inc. by companies like American Century Companies Inc. indicate confidence in the company's future prospects, which could positively impact its stock performance.
  • Positive Wall Street analyst ratings, such as the "market outperform" rating from JMP Securities, suggest a favorable outlook for Zimmer Biomet Holdings, Inc., potentially attracting more investors.
  • Despite fluctuations in stock price, Zimmer Biomet Holdings, Inc. has a strong history of serving healthcare professionals and patients, positioning it as a reliable player in the surgical appliances & supplies industry.

Cons

Investors should be bearish about investing in Zimmer Biomet Holdings, Inc. for these reasons:

  • Recent adjustments in price targets by analysts, like the reduction from $160.00 to $140.00 by JMP Securities, may indicate potential challenges or uncertainties in the company's financial performance or market conditions.
  • Transitioning from a "strong-buy" to a "buy" rating by StockNews.com could suggest a shift in market sentiment towards Zimmer Biomet Holdings, Inc., prompting caution among investors regarding the stock's future growth potential.
  • While Zimmer Biomet Holdings, Inc. has a strong presence in the orthopedic products market, increasing competition and evolving healthcare trends could pose challenges to maintaining market share and profitability in the long term.
  • The hold rating from Canaccord Genuity Group may signal a neutral stance on Zimmer Biomet Holdings, Inc., indicating a lack of significant catalysts or growth drivers that could attract substantial investor interest in the near future.
  • Investors should consider the impact of external factors, such as regulatory changes or global economic conditions, on Zimmer Biomet Holdings, Inc.'s operations and financial performance, as these could influence investment outcomes.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, April 9, 2024. Please send any questions or comments about these Zimmer Biomet pros and cons to contact@marketbeat.com.

ZBH Stock Analysis - Frequently Asked Questions

Should I buy or sell Zimmer Biomet stock right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zimmer Biomet in the last twelve months. There are currently 1 sell rating, 9 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ZBH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZBH, but not buy additional shares or sell existing shares.
View ZBH analyst ratings
or view top-rated stocks.

What is Zimmer Biomet's stock price target for 2024?

15 Wall Street analysts have issued 12-month price objectives for Zimmer Biomet's stock. Their ZBH share price targets range from $120.00 to $172.00. On average, they predict the company's share price to reach $139.39 in the next year. This suggests a possible upside of 12.0% from the stock's current price.
View analysts price targets for ZBH
or view top-rated stocks among Wall Street analysts.

How have ZBH shares performed in 2024?

Zimmer Biomet's stock was trading at $121.70 at the beginning of 2024. Since then, ZBH stock has increased by 2.3% and is now trading at $124.48.
View the best growth stocks for 2024 here
.

When is Zimmer Biomet's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ZBH earnings forecast
.

How can I listen to Zimmer Biomet's earnings call?

Zimmer Biomet will be holding an earnings conference call on Thursday, May 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Zimmer Biomet's earnings last quarter?

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) issued its quarterly earnings results on Thursday, February, 8th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.15 by $0.05. The medical equipment provider earned $1.94 billion during the quarter, compared to analyst estimates of $1.93 billion. Zimmer Biomet had a net margin of 13.85% and a trailing twelve-month return on equity of 12.79%. The business's quarterly revenue was up 6.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.88 EPS.
Read the conference call transcript
.

How often does Zimmer Biomet pay dividends? What is the dividend yield for Zimmer Biomet?

Zimmer Biomet announced a quarterly dividend on Wednesday, February 21st. Investors of record on Friday, March 29th will be paid a dividend of $0.24 per share on Tuesday, April 30th. This represents a $0.96 annualized dividend and a yield of 0.77%. The ex-dividend date is Wednesday, March 27th.
Read our dividend analysis for ZBH
.

Is Zimmer Biomet a good dividend stock?

Zimmer Biomet (NYSE:ZBH) pays an annual dividend of $0.96 per share and currently has a dividend yield of 0.77%. The dividend payout ratio is 19.63%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ZBH will have a dividend payout ratio of 11.02% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ZBH.

What guidance has Zimmer Biomet issued on next quarter's earnings?

Zimmer Biomet updated its FY 2024 earnings guidance on Thursday, February, 8th. The company provided EPS guidance of 8.000-8.150 for the period, compared to the consensus EPS estimate of 7.940. The company issued revenue guidance of $7.7 billion-$7.8 billion, compared to the consensus revenue estimate of $7.7 billion.

What is Bryan Hanson's approval rating as Zimmer Biomet's CEO?

240 employees have rated Zimmer Biomet Chief Executive Officer Bryan Hanson on Glassdoor.com. Bryan Hanson has an approval rating of 87% among the company's employees. 66.0% of employees surveyed would recommend working at Zimmer Biomet to a friend.

What other stocks do shareholders of Zimmer Biomet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zimmer Biomet investors own include AT&T (T), Walt Disney (DIS), Johnson & Johnson (JNJ), Bristol-Myers Squibb (BMY), Cisco Systems (CSCO), Merck & Co., Inc. (MRK), Intel (INTC), AbbVie (ABBV), NVIDIA (NVDA) and JPMorgan Chase & Co. (JPM).

Who are Zimmer Biomet's major shareholders?

Zimmer Biomet's stock is owned by many different retail and institutional investors. Top institutional investors include Douglas Lane & Associates LLC (0.25%), Thomasville National Bank (0.04%), ST Germain D J Co. Inc. (0.04%), Factory Mutual Insurance Co. (0.04%), Centre Asset Management LLC (0.04%) and Reinhart Partners LLC. (0.04%). Insiders that own company stock include Arthur J Higgins, Arthur J Higgins, Betsy J Bernard, Chad F Phipps, Michael W Michelson, Robert Hagemann, Sang Yi, Sreelakshmi Kolli and Zuilen Wilfred Van.
View institutional ownership trends
.

How do I buy shares of Zimmer Biomet?

Shares of ZBH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Zimmer Biomet have any subsidiaries?
The following companies are subsidiares of Zimmer Biomet: Abbott Spine, Beijing Montagne Medical Device Co. Ltd., Beijing Montagne Medical Device Co. Ltd., BioMet, Biomet 3i Australia Pty. Ltd., Biomet 3i Belgium N.V., Biomet 3i Benelux Holdings N.V., Biomet 3i Dental Iberica SL, Biomet 3i LLC, Biomet 3i Mexico S.A. de C.V., Biomet 3i Netherlands B.V., Biomet 3i Nordic AB, Biomet 3i Portugal Lda, Biomet 3i Switzerland GmbH, Biomet 3i Turkey, Biomet 3i UK Ltd., Biomet 3i do Brasil Comercio de Aparelhos Medicos Ltda., Biomet Acquisitions (Unlimited), Biomet Argentina SA, Biomet Australia Pty. Ltd., Biomet Biologics LLC, Biomet Brazil Medical Device Ltda., Biomet C.V., Biomet CV Holdings LLC, Biomet Cementing Technologies AB, Biomet Chile SA, Biomet China Co. Ltd., Biomet Deutschland GmbH, Biomet Deutschland Holding GmbH, Biomet Fair Lawn LLC, Biomet Finance US LLC, Biomet France Sarl, Biomet Global Supply Chain Center B.V., Biomet Healthcare Management GmbH, Biomet Holdings B.V., Biomet Hong Kong CBT Ltd., Biomet Hong Kong Holding Ltd., Biomet Hong Kong No. 1 Ltd., Biomet Inc., Biomet Insurance Ltd., Biomet International Inc., Biomet International Orthopedics LLC, Biomet Leasing Inc., Biomet Manufacturing LLC, Biomet Mexico S.A. de C.V., Biomet Microfixation B.V., Biomet Orthopedics LLC, Biomet Orthopedics Puerto Rico Inc., Biomet Spain Orthopaedics S.L., Biomet Sports Medicine LLC, Biomet Trauma LLC, Biomet U.S. Reconstruction LLC, Biomet UK Healthcare Ltd., Biomet UK Ltd., CD Diagnostics, CD Diagnostics Inc., CD Laboratories Inc., Cayenne Medical, Cayenne Medical Inc., CelgenTek Innovations Corporation, Centerpulse Ltd, Changzhou Biomet Medical Devices Co. Ltd., Citra Labs LLC, Clinical Graphics, Compression Therapy Concepts Inc., Compression Therapy Products, D.S. Comp Ltd., Dornoch Medical Systems, Dornoch Medical Systems Inc., EBI Holdings LLC, EBI LLC, EBI Medical Systems LLC, EBI Patient Care Inc., ETEX Corporation, ETEX Holdings Inc., Electro-Biology LLC, Endius, Espanormed S.L., Etex, ExtraOrtho, Hakuho Company Ltd., IC Guided Surgery SRL, Implant Concierge LLC, Implant Innovations Holdings LLC, Implex, InnoVision Inc., Interpore Cross International LLC, JERDS Luxembourg Holding Sarl, Kirschner Medical Corporation, Knee Creations, LDR Brasil Comercio Importacao e Exportacao Ltda., LDR Holding, LDR Medical Hong Kong (branch), LDR Médical S.A.S., LVB Acquisition Inc., Lanx Puerto Rico LLC , Lanx Srl, Medical Compression Systems Inc., Medtech SA, Medtech SAS, Medtech Surgical GmbH, Medtech Surgical Inc., NORMED Medizin-Technik GmbH, ORTHOsoft ULC, Ortho Transmission, Orthopaedic Advantage LLC, Ospol Participacoes Ltda., Representaciones Zimmer Inc. S. de R.L. de C.V., Respondwell, SM Re Ltd., Scandimed Holding AB, Shanghai Biomet Business Consulting Co. Ltd., Synvasive Technology, Synvasive Technology Inc., ZB COOP C.V., ZB COOP LLC, ZB Cayman (Asia) Holding Ltd., ZB Cayman Island CBT 2 Ltd., ZB Dental India Private Limited, ZB EMEA 1 LP, ZB EMEA Finance UK 1 Ltd., ZB EMEA Finance UK 2 Ltd., ZB EMEA Finance UK 3 Ltd., ZB EMEA US UK LLC, ZB Hong Kong CBT 2 Ltd., ZB Hong Kong Holding Ltd., ZB Hong Kong Ltd., ZB Manufacturing LLC, ZB UK Group Holdings Limited, ZH2LX Barbados Branch (branch), Zfx, Zfx GmbH, Zfx Innovation GmbH, Zhejiang Biomet Medical Products Co. Ltd., Zimmer (Shanghai) Medical International Trading Co. Ltd., Zimmer Asia (HK) Ltd., Zimmer Australia Holding Pty. Ltd., Zimmer Biomet (Thailand) Co. Ltd., Zimmer Biomet Asel Alarabiya Limited Company, Zimmer Biomet Asia Holding B.V., Zimmer Biomet Asia Holdings Pte. Ltd., Zimmer Biomet Austria GmbH, Zimmer Biomet BVBA, Zimmer Biomet CBT, Zimmer Biomet CBT 2, Zimmer Biomet CMF and Thoracic LLC, Zimmer Biomet Canada Inc., Zimmer Biomet Centroamerica SA, Zimmer Biomet Comp Ltd., Zimmer Biomet Denmark ApS, Zimmer Biomet Dental Canada Inc., Zimmer Biomet Dental K.K., Zimmer Biomet Deutschland GmbH, Zimmer Biomet Distribution LLC, Zimmer Biomet Finance Srl, Zimmer Biomet Finance US Holding Inc., Zimmer Biomet Finland Oy, Zimmer Biomet France Holdings SAS, Zimmer Biomet France SAS, Zimmer Biomet GK, Zimmer Biomet Global Holdings Switzerland GmbH, Zimmer Biomet Hellas SA, Zimmer Biomet Ireland Limited, Zimmer Biomet Italia Srl, Zimmer Biomet Korea Ltd., Zimmer Biomet Nederland B.V., Zimmer Biomet New Zealand Company, Zimmer Biomet Norway AS, Zimmer Biomet OUS Holdings AG, Zimmer Biomet Polska Sp. z.o.o, Zimmer Biomet Portugal Unipessoal Lda, Zimmer Biomet Pty. Ltd., Zimmer Biomet Romania S.R.L., Zimmer Biomet South Africa (Pty) Ltd., Zimmer Biomet Spain S.L., Zimmer Biomet Spine Inc., Zimmer Biomet Sweden AB, Zimmer Biomet Taiwan Co. Ltd., Zimmer Biomet UK Ltd., Zimmer Biomet US 2 Holding Inc., Zimmer CBT I Holding Inc., Zimmer CBT II Holding Inc., Zimmer CEP USA Holding Co., Zimmer CEP USA Inc., Zimmer CIS Ltd., Zimmer CV Inc., Zimmer Caribe LLC, Zimmer Cayman Islands Holding Co. Ltd., Zimmer Co-op Holdings LLC, Zimmer Colombia SAS, Zimmer Czech sro, Zimmer Dental (Shanghai) Medical Device Co. Ltd., Zimmer Dental Chile Spa, Zimmer Dental GmbH, Zimmer Dental Inc., Zimmer Dental Italy Srl, Zimmer Dental Ltd., Zimmer Dental SAS, Zimmer Finance Ireland, Zimmer France Manufacturing Sarl, Zimmer Germany Holdings GmbH, Zimmer GmbH, Zimmer GmbH Euro IP Branch (branch), Zimmer GmbH Winterthur Branch (branch), Zimmer Gulf FZ LLC, Zimmer Inc., Zimmer India Private Ltd., Zimmer International Logistics GmbH, Zimmer Investments LLC, Zimmer Knee Creations Inc., Zimmer Luxembourg II Sarl, Zimmer Luxembourg Sarl, Zimmer Manufacturing B.V., Zimmer Manufacturing B.V. (branch), Zimmer Medical Malaysia SDN BHD, Zimmer Netherlands Cooperatief U.A., Zimmer Orthobiologics Inc., Zimmer Orthopedics Manufacturing Limited, Zimmer Production Inc., Zimmer Pte. Ltd., Zimmer Slovakia sro, Zimmer Southeast Florida LLC, Zimmer Spine Next Inc., Zimmer Spine SAS, Zimmer Surgical, Zimmer Surgical Inc., Zimmer Surgical SA, Zimmer Switzerland Holdings LLC, Zimmer Switzerland Manufacturing GmbH, Zimmer Tibbi Cihazlar Sanayi ve Ticaret AS, Zimmer Trabecular Metal Technology Inc., Zimmer Trustee Ltd., Zimmer UK Limited, Zimmer US Inc., and Zimmer do Brasil Comercio Ltda..
Read More
This page (NYSE:ZBH) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners